NeurAxis Expands Payer Coverage with New Policies
Rhea-AI Summary
NeurAxis (NYSE American: NRXS) announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, adding access for over 500,000 covered lives and expanding IB-Stim availability for beneficiaries in the Mid-Atlantic region.
According to NeurAxis, this incremental coverage supports its strategy to achieve comprehensive nationwide written policy coverage for IB-Stim. The company highlights implementation of a Category I CPT code and inclusion of its PENFS technology in leading clinical guidelines as reinforcing IB-Stim’s clinical and economic value among payers. IB-Stim is FDA-cleared for functional abdominal pain associated with IBS and functional dyspepsia, including FD-related nausea, in patients 8 years and older, and is positioned as the only FDA-cleared therapy specifically designed for pediatric abdominal pain-related DGBIs.
Positive
- Over 500,000 additional covered lives for PENFS/IB-Stim in Mid-Atlantic
- Growing payer network supported by Category I CPT code and guideline inclusion
- IB-Stim positioned as the only FDA-cleared therapy for pediatric abdominal pain-related DGBIs
- Company cites a strong balance sheet to support commercial expansion
Negative
- None.
News Explained
The release describes NeurAxis’ balance sheet as strong; its latest supplied quarter reported
Sources and calculations
- NeurAxis Expands Payer Coverage with New Policies (2026-08-04)
- NeurAxis latest-quarter fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $7,078,659 / ($1,229,757 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 28 | Earnings call scheduling | Neutral | -3.1% | Second-quarter results call scheduled for August 11 before market open |
| May 12 | Quarterly earnings report | Positive | +1.5% | Record first-quarter revenue and improved gross margin supported by insurance coverage |
| May 05 | Earnings call scheduling | Neutral | +4.7% | First-quarter results call scheduled for May 12 before market open |
| Apr 22 | Payer coverage expansion | Positive | +3.2% | Four new medical policies added approximately 1.25 million covered lives |
| Apr 10 | Preferred stock dividend | Negative | -5.7% | Stock dividend expected to issue approximately 510,605 common shares |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: prior payer-coverage news aligned with a positive reaction, while scheduling notices diverged and a preferred-stock dividend aligned with a negative reaction.
Key Terms
percutaneous electrical nerve field stimulation medical
neuromodulation medical
functional dyspepsia medical
disorders of gut-brain interaction medical
category i cpt code regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
“As we continue to make meaningful progress with the nation's largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,” said Brian Carrico, CEO of NeurAxis. “We continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT code, together with the inclusion of our PENFS technology in leading clinical guidelines, is reinforcing IB-Stim's clinical and economic value among payers. Supported by a strong balance sheet, we are well positioned to expand our commercial organization as reimbursement coverage grows and demand for IB-Stim continues to increase.”
NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
